DrugPatentWatch Database Preview
TPOXX Drug Profile
When do Tpoxx patents expire, and what generic alternatives are available?
Tpoxx is a drug marketed by Siga Technologies and is included in one NDA. There are six patents protecting this drug.
This drug has sixty patent family members in twenty countries.
The generic ingredient in TPOXX is tecovirimat. One supplier is listed for this compound. Additional details are available on the tecovirimat profile page.
Summary for TPOXX
| International Patents: | 60 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 16 |
| Patent Applications: | 12 |
| DailyMed Link: | TPOXX at DailyMed |
Generic Entry Opportunity Date for TPOXX
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Synonyms for TPOXX
| 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop(f)isoindol-2(1H)-yl)-benzamide |
| 458T318 |
| 816458-31-8 |
| 869572-92-9 |
| 935766-08-8 |
| 935839-17-1 |
| AKOS030260536 |
| AN-27268 |
| Benzamide, N-((3aR,4R,4aR,5aS,6S,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop(f)isoindol-2(1H)-yl)-4-(trifluoromethyl)-, rel- |
| Benzamide, N-[(3aR,4R,4aR,5aS,6S,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl]-4-(trifluoromethyl)-, rel- |
| CHEMBL1257073 |
| CS-3464 |
| D08FOR |
| DB12020 |
| F925RR824R |
| HY-14805 |
| KB-80732 |
| N-((3aR,4R,4aR,5aS,6S,6aS)-1,3-Dioxo-3,3a,4,4a,5,5a,6,6a-octahydro-4,6-ethenocyclopropa(f)isoindol-2(1H)-yl)-4-(trifluoromethyl)benzamide |
| N-((3aR,4R,4aR,5aS,6S,6aS)-1,3-dioxo-3,3a,4,4a,5,5a,6,6a-octahydro-4,6-ethenocyclopropa[f]isoindol-2(1H)-yl)-4-(trifluoromethyl)benzamide |
| N-(dioxo[?]yl)-4-(trifluoromethyl)benzamide |
| N-[(3aR,4R,4aR,5aS,6S,6aS)-1,3-Dioxooctahydro-4,6-ethenocyclopropa[f]isoindol-2(1H)-yl]-4-(trifluoromethyl)benzamide |
| P37 envelope protein inhibitor (smallpox virus), SIGA |
| SCHEMBL404743 |
| SIGA 246 |
| SIGA-246 |
| ST 246 |
| ST-246 |
| Tecovirimat |
| Tecovirimat [USAN:INN] |
| UNII-F925RR824R |
| ZINC35323125 |
US Patents and Regulatory Information for TPOXX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Siga Technologies | TPOXX | tecovirimat | CAPSULE;ORAL | 208627-001 | Jul 13, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Siga Technologies | TPOXX | tecovirimat | CAPSULE;ORAL | 208627-001 | Jul 13, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Siga Technologies | TPOXX | tecovirimat | CAPSULE;ORAL | 208627-001 | Jul 13, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Siga Technologies | TPOXX | tecovirimat | CAPSULE;ORAL | 208627-001 | Jul 13, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Siga Technologies | TPOXX | tecovirimat | CAPSULE;ORAL | 208627-001 | Jul 13, 2018 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for TPOXX
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Russian Federation | 2578606 | ➤ Sign Up |
| Singapore | 184201 | ➤ Sign Up |
| South Africa | 201207141 | ➤ Sign Up |
| Mexico | 2009011533 | ➤ Sign Up |
| Japan | 2016040323 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
